Embryo Developmental Potential in a Novel 2-step IVM System
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Feb 24, 2020
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
The current IVM system in use in the clinic has a single step approach and seems to be less efficient compared to research and literature findings using a biphasic CAPA-IVM system in terms of maturation.
To ascertain the efficiency of the biphasic CAPA-IVM system, both standard IVM and CAPA-IVM will be performed on sibling oocytes: maturation in standard IVM in the investigator's center is on average 47.5%, where CAPA-IVM reaches 62% maturation in literature.
The investigators aim to prove superiority of the CAPA-IVM system in terms of maturation. Also fertilization and embryo development...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • PCO(S) patients
- • Anti-Mullerian Hormone ≥ 3.6 ng/mL
- • Basal Antral Follicle Count ≥ 20
- • All ranks of trial
- Exclusion Criteria:
- • Surgically obtained semen sample
- • Grade 3 or 4 endometriosis, minor or major uterine abnormalities
- • Preimplantation Genetic Testing
- • Priming with Letrozole
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Trial Officials
Michel De Vos, MD, PhD
Principal Investigator
VUB- UZ Brussel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials